Blueprint Medicines Corporation
BPMCNext catalyst
BLU-808
Chronic Inducible Urticaria
Get an email about BPMC's next catalysts
Track Blueprint Medicines (BPMC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 0 past
BLU-808 Phase 2 Est. Readout
Primary completion for BLU-808 trial (NCT06931405) in Chronic Inducible Urticaria
SourceAvapritinib Phase 2 Est. Readout
Primary completion for Avapritinib trial (NCT03731260) in Indolent Systemic Mastocytosis
SourceMarket Overview
Stock performance and key metrics
Elenestinib
Indolent Systemic Mastocytosis
avapritinib
Solid Tumor, Unspecified, Child
regorafenib
GIST
Phase Ib: Fisogatinib (BLU-554) in combination with Sugemalimab (CS1001)
Hepatocellular Carcinoma
BLU-808
Chronic Inducible Urticaria
Phase II: Fisogatinib (BLU-554) in combination with Sugemalimab (CS1001)
Hepatocellular Carcinoma
BLU-924
Advanced Solid Tumor
CS3007 (BLU-285)
Gastrointestinal Stromal Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Elenestinib | Phase 3 | Indolent Systemic Mastocytosis | - | - |
avapritinib | Phase 3 | Solid Tumor, Unspecified, Child | - | - |
regorafenib | Phase 3 | GIST | - | - |
Phase Ib: Fisogatinib (BLU-554) in combination with Sugemalimab (CS1001) | Phase 2 | Hepatocellular Carcinoma | - | - |
BLU-808 | Phase 2 | Chronic Inducible Urticaria | - | - |
Phase II: Fisogatinib (BLU-554) in combination with Sugemalimab (CS1001) | Phase 2 | Hepatocellular Carcinoma | - | - |
BLU-924 | Phase 2 | Advanced Solid Tumor | - | - |
CS3007 (BLU-285) | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Indolent Systemic Mastocytosis
2 drugs in this indication
GIST
1 drug in this indication
Solid Tumor, Unspecified, Child
1 drug in this indication
Chronic Inducible Urticaria
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Blueprint Medicines Corporation's drug pipeline?→
CatalystAlert tracks 8 drug candidates in Blueprint Medicines Corporation's (BPMC) pipeline across Phase 3, Phase 2. Its lead program is avapritinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Blueprint Medicines Corporation's next FDA catalyst?→
Blueprint Medicines Corporation's (BPMC) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BPMC biotech catalysts?→
Add BPMC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Blueprint Medicines Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.